Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hock, C.
Right arrow Articles by Otten, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hock, C.
Right arrow Articles by Otten, U.
Neurology 2000;54:2009-2011
© 2000 American Academy of Neurology
Brief Communications

Increased CSF levels of nerve growth factor in patients with Alzheimer’s disease

C. Hock, MD, K. Heese, PhD, F. Müller-Spahn, MD, P. Huber, PhD, W. Riesen, PhD, R. M. Nitsch, MD and U. Otten, MD, PhD

From the Department of Psychiatry Research (Drs. Hock and Nitsch), University of Zürich, Switerzland; the Departments of Physiology (Drs. Heese and Otten), Psychiatry (Dr. Müllar-Spahn), and Clinical Chemistry (Dr. Huber), University of Basel, Switzerland; BF Research Institute (Dr. Hesse), National Cardiovascular Center, Osaka, Japan; and Institute for Clinical Chemistry and Hematology (Dr. Riesen), State Hospital St. Gallen, Switzerland.

Address correspondence and reprint requests to Dr. Christoph Hock, Department of Psychiatry Research, University of Zürich, Lenggstrasse 31, CH-8029 Zürich, Switzerland.

The authors quantitated CSF levels of nerve growth factor (NGF) in patients with AD, nondemented control subjects (CTR), and age-matched patients with major depression (DE). CSF levels of NGF were markedly higher in the AD group than in both the CTR and DE groups (p < 0.01 and p < 0.001). Increased CSF levels of NGF in AD patients may reflect reported accumulation of NGF in the AD brain and may constitute a candidate marker for clinical diagnosis and therapeutic monitoring.

Key words: Neurotrophins—Basal forebrain—Dementia—ELISA.




This article has been cited by other articles:


Home page
 J. Neurosci.Home page
M. A. Bruno, P. B. S. Clarke, A. Seltzer, R. Quirion, K. Burgess, A. C. Cuello, and H. U. Saragovi
Long-Lasting Rescue of Age-Associated Deficits in Cognition and the CNS Cholinergic Phenotype by a Partial Agonist Peptidomimetic Ligand of TrkA
J. Neurosci., September 15, 2004; 24(37): 8009 - 8018.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
E. J. Mufson, M. D. Ikonomovic, S. D. Styren, S. E. Counts, J. Wuu, S. Leurgans, D. A. Bennett, Elizabeth. J. Cochran, and S. T. DeKosky
Preservation of Brain Nerve Growth Factor in Mild Cognitive Impairment and Alzheimer Disease
Arch Neurol, August 1, 2003; 60(8): 1143 - 1148.
[Abstract] [Full Text] [PDF]

Home page
 AJGPHome page
J. Neugroschl and K. L. Davis
Biological Markers in Alzheimer Disease
Am J Geriatr Psychiatry, December 1, 2002; 10(6): 660 - 677.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Y. Y. Hu, S. S. He, X. Wang, Q. H. Duan, I. Grundke-Iqbal, K. Iqbal, and J. Wang
Levels of Nonphosphorylated and Phosphorylated Tau in Cerebrospinal Fluid of Alzheimer's Disease Patients : An Ultrasensitive Bienzyme-Substrate-Recycle Enzyme-Linked Immunosorbent Assay
Am. J. Pathol., April 1, 2002; 160(4): 1269 - 1278.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by AAN Enterprises, Inc.